Susan Silbermann is President and General Manager of Pfizer Vaccines. In her role, Susan oversees a global business and is responsible for the commercial development of a visionary pipeline portfolio of preventative and therapeutic vaccines to address unmet medical needs and treat serious or life-threatening conditions. Susan leads a team that partners with government and global civic organizations to maximize Pfizer’s impact on public health. Pfizer is proud to collaborate with Gavi, the Vaccine Alliance, as we have a shared goal  ̶  “to protect the world’s most vulnerable children through a sustainable vaccine program.”  Through this collaboration, Pfizer contributes to Gavi’s goal of immunizing a further 300 million people from 2016 to 2020. Prior to this position, Susan was the regional president of Latin America within Pfizer’s Emerging Markets Business Unit. In this role, she managed Pfizer’s pharmaceutical operations in a diverse market with more than 20 countries, each with varying health needs and priorities. Throughout her nearly 30-year career at Pfizer, Susan has held numerous leadership positions in Marketing, Commercial Development and General Management in the U.S. and international markets. She holds a seat on the International Federation of Pharmaceutical Manufacturers & Associations Vaccine CEO Steering Committee. In addition, Susan serves on the boards of advisors for Catalyst Inc., a nonprofit organization that promotes inclusive workplaces for women, and on the corporate advisory board for the Johns Hopkins University Carey Business School  ̶  “Where business is taught with humanity in mind.” Susan has a B.S. in biology and French from Tufts University, and a joint M.B.A./M.A. degree in international business and French studies from the Stern Graduate School of Business and the Institute of French Studies at New York University.

 preventative and therapeutic vaccines